Literature DB >> 26948315

Treatment for neovascular age related macular degeneration: The state of the art.

Chiara M Eandi1, Camilla Alovisi2, Ugo De Sanctis2, Federico M Grignolo2.   

Abstract

With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Anti-VEGF; Choroid; Degeneration; Macula; Retina

Mesh：

Substances：

Year:  2016        PMID： 26948315     DOI： 10.1016/j.ejphar.2016.03.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  8 in total

1.  Oral Doxycycline Reduces the Total Number of Intraocular Bevacizumab Injections Needed to Control Neovascular Age-related Macular Degeneration.

Authors:  Ahmad Mirshahi; Pourya Azimi; Ali Abdolahi; Romina Mirshahi; Mahnaz Abdollahian
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2017

Review 2.  The Question of a Role for Statins in Age-Related Macular Degeneration.

Authors:  Marina Roizenblatt; Nara Naranjit; Mauricio Maia; Peter L Gehlbach
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

Review 3.  IGF-1, Inflammation and Retinal Degeneration: A Close Network.

Authors:  Ana I Arroba; Antonio Campos-Caro; Manuel Aguilar-Diosdado; Ángela M Valverde
Journal:  Front Aging Neurosci       Date:  2018-07-05       Impact factor: 5.750

4.  Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway.

Authors:  Eveline Kersten; Sascha Dammeier; Soufiane Ajana; Joannes M M Groenewoud; Marius Codrea; Franziska Klose; Yara T Lechanteur; Sascha Fauser; Marius Ueffing; Cécile Delcourt; Carel B Hoyng; Eiko K de Jong; Anneke I den Hollander
Journal:  PLoS One       Date:  2019-06-20       Impact factor: 3.240

5.  Expression of VEGFA-regulating miRNAs and mortality in wet AMD.

Authors:  Janusz Blasiak; Cezary Watala; Raimo Tuuminen; Niko Kivinen; Ali Koskela; Hannele Uusitalo-Järvinen; Anja Tuulonen; Mateusz Winiarczyk; Jerzy Mackiewicz; Szymon Zmorzyński; Agata Filip; Kai Kaarniranta
Journal:  J Cell Mol Med       Date:  2019-10-21       Impact factor: 5.310

6.  Metabolomics in Age-Related Macular Degeneration: A Systematic Review.

Authors:  Xiao-Wen Hou; Ying Wang; Chen-Wei Pan
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

Review 7.  A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases.

Authors:  Sanjucta Adak; Damaris Magdalene; Saurabh Deshmukh; Dipankar Das; Bithiah Grace Jaganathan
Journal:  Stem Cell Rev Rep       Date:  2021-01-06       Impact factor: 6.692

Review 8.  Stem Cell Therapy for Retinal Degeneration: The Evidence to Date.

Authors:  Amit Sharma; Bithiah Grace Jaganathan
Journal:  Biologics       Date:  2021-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.